secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-05-26T13:26:00+00:00
Accession:  0001104659-26-066062
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference
--------------------------------------------------------------------------------

- 16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.
- In participants with elevated baseline CSF GluSph, levels dropped an average of 81% after 90 days.
- At Day 150, high-baseline GluSph group showed 4.8-point greater improvement in MDS-UPDRS Parts II+III vs low-baseline group.
- Unsolicited patient reports: improved smell/taste (4), balance/gait (4), and sleep (3) after 90 days.
- Planned Phase 2 will add UPSIT smell test and Opal wearable gait assessments as endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/0001104659-26-066062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/tm2615594d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer